Oxygen Single Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/178)
  • Patent number: 10238662
    Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: March 26, 2019
    Assignee: ANTARES PHARMA, INC.
    Inventors: Paul K. Wotton, Hermanus L. Jooste, Kaushik J. Dave, Jon Jaffe
  • Patent number: 10226473
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: March 12, 2019
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Patent number: 10166245
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: January 1, 2019
    Assignee: Cassiopea S.P.A.
    Inventors: Mauro Ajani, Luigi Moro
  • Patent number: 10159682
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 25, 2018
    Assignee: CASSIOPEA S.P.A.
    Inventors: Mauro Ajani, Luigi Moro
  • Patent number: 10130713
    Abstract: A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: November 20, 2018
    Assignees: THE METHODIST HOSPITAL, UNIVERSITY OF HOUSTON SYSTEM
    Inventors: Anders Berkenstam, Edward Kuczynski, Alf S. Andersson, Jan-Ake Gustafsson, Carly Sue Filgueira
  • Patent number: 10092610
    Abstract: The present invention relates to a tall oil fatty acid for use in the prevention of growth of harmful bacteria in the animal digestive tract and/or in the prevention of intestinal disorders. The invention further relates to a feed supplement and a feed composition comprising tall oil fatty acid.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: October 9, 2018
    Assignee: Hankkija Oy
    Inventors: Juhani Vuorenmaa, Hannele Kettunen
  • Patent number: 10076525
    Abstract: Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: September 18, 2018
    Assignee: ENDORECHERCHE, INC.
    Inventors: Mohamed El-Alfy, Fernand Labrie, Louise Berger
  • Patent number: 10016384
    Abstract: The subject invention relates to a variety of formulations of bipolar trans carotenoids including pharmaceutical compositions for oral delivery of a bipolar trans carotenoid comprising i) a bipolar trans carotenoid, ii) a cyclodextrin, and iii) a coating. The invention also relates to preparation of such formulations and their uses.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: July 10, 2018
    Assignee: DIFFUSION PHARMACEUTICALS LLC
    Inventors: John L. Gainer, Robert Murray
  • Patent number: 9974834
    Abstract: A method of diagnosing a subject's percentage of probability of retrieval of oocytes based on an age of the subject by selecting the percentage that matches the subject's AMR level in accord with plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes and administering AMR to the subject, as warranted, to increase the AMR level to attain a desired percentage of probability of retrieval of oocytes based upon the age of the subject and in accord with a matching percentage for the increased AMR level from plotted curves for retrieval of ?1, ?2, ?3, ?4 and ?5 oocytes.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 22, 2018
    Assignee: AMERICAN INFERTILITY OF NEW YORK, P.C.
    Inventors: Norbert Gleicher, Vitaly A. Kushnir, David H. Barad
  • Patent number: 9895379
    Abstract: The present application provides 17 and/or 21 esters of 17?,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17?,21-dihydroxypregna-4-ene-3,20-dione having remarkable antiandrogenic activity, methods of using these compounds, and processes for their preparation.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: February 20, 2018
    Assignee: CASSIOPEA S.P.A.
    Inventors: Mauro Ajani, Luigi Moro
  • Patent number: 9867795
    Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: January 16, 2018
    Assignees: The UAB Research Foundation, The State of Oregon Acting by and through the State Board of Higher Education on Behalf of the University of Oregon, University College Cardiff Consultants Limited, Morehouse School of Medicine, Inc.
    Inventors: Bruce A. Freeman, Francisco Schopfer, Valerie O'Donnell, Paul Baker, Yuqing E. Chen, Bruce Branchaud
  • Patent number: 9757389
    Abstract: Disclosed are bioavailable solid state (17-?)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-?)-Hydroxy-4-Androsten-3-one.
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: September 12, 2017
    Assignee: Lipocine Inc.
    Inventors: Mahesh V. Patel, Nachiappan Chidambaram, Satish Kumar Nachaegari, Srinivasan Venkateshwaran, Joel Frank
  • Patent number: 9724391
    Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a corticosteroid and exosomes. By means of the combination therapy diseases such as osteoarthritis, arthritis and/or degenerative spinal diseases can be treated.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: August 8, 2017
    Assignee: ORTHOGEN AG
    Inventors: Peter Wehling, Julio Reinecke
  • Patent number: 9682088
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 20, 2017
    Assignees: LABORATOIRE HRA-PHARMA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
  • Patent number: 9598459
    Abstract: This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 21, 2017
    Assignee: Pop Test Oncology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
  • Patent number: 9532995
    Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: January 3, 2017
    Assignee: MISCON TRADING S.A.
    Inventor: Mirudhubashini Govindarajan
  • Patent number: 9522156
    Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: December 20, 2016
    Assignees: The UAB Research Foundation, The State of Oregon Acting by and through the State Board of Higher Education on Behalf of the University of Oregon, University College Cardiff Consultants Limited, Morehouse School of Medicine, Inc.
    Inventors: Bruce A. Freeman, Francisco Schopfer, Valerie O'Donnell, Paul Baker, Yuqing E. Chen, Bruce Branchaud
  • Patent number: 9486458
    Abstract: The present invention refers to a new enzymatic process for obtaining 17?-monoesters of cortexolone and/or its 9,11-dehydroderivatives starting from the corresponding 17?,21-diesters which comprises an enzymatic alcoholysis reaction. Furthermore, the present invention refers to new crystalline forms of cortexolone-17?-propionate and 9,11-dehydro-cortexolone 17?-butanoate.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 8, 2016
    Assignee: Cassiopea SPA
    Inventors: Mauro Ajani, Luigi Moro
  • Patent number: 9480690
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: November 1, 2016
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Nachiappan Chidambaram, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Patent number: 9446049
    Abstract: The basic formulation comprises a combination of three estrogens, 2-hydroxyestrone, 17-beta-estradiol and estriol, and a metabolite of an estrogen, 2-methoxyestradiol, in specified amounts. Amounts of folic acid, DHEA, testosterone, Vitamin B6, Di-Indolyl Methane, melatonin and progesterone, as well as selenium and cobalt can be added in specific amounts to the basic formulation. 2-Hydroxyestradiol, another metabolic, can also be added.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: September 20, 2016
    Inventor: Jonathan V. Wright
  • Patent number: 9358299
    Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 7, 2016
    Assignee: LIPOCINE INC
    Inventors: Chandrashekar Giliyar, Srinivansan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
  • Patent number: 9351818
    Abstract: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogs, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 31, 2016
    Assignee: Thorn Bioscience LLC
    Inventor: James W. Lauderdale
  • Patent number: 9333190
    Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast diseases and diseases susceptible to endoxifen. In particular, the compositions of the present invention include liposomes, complexes, vesicles, emulsions, micelles and mixed micelles of endoxifen in which the compositions further contain any of a variety of neutral or charged lipids and desirably, cholesterol and cholesterol derivatives, sterols, Z- and E-guggulsterones, phospholipids, fatty acids, vitamin D, and vitamin E. The present invention also provides methods of preparing endoxifen. The present invention provides methods for treating and preventing breast cancer and other breast related diseases by administrating novel formulations or compositions comprising a therapeutically effective amount of endoxifen.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: May 10, 2016
    Assignee: JINA PHARMACEUTICALS, INC.
    Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
  • Patent number: 9283234
    Abstract: The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: March 15, 2016
    Assignee: REPROS THERAPEUTICS INC.
    Inventor: Joseph S. Podolski
  • Patent number: 9278072
    Abstract: The present invention relates to a hormonal contraceptive including 21 to 25 hormone-containing daily units, which contain a combination of ethinyloestradiol in an amount of ?25 ?g and chlormadinone acetate in an amount of ?5 mg, and optionally 7 to 3 hormone-free daily units for oral administration to women.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: March 8, 2016
    Assignee: Richter Gedeon Nyrt.
    Inventors: Janine Klose, Johannes Bartholomäus, Klaus-Michael Wilsmann, Georg Schramm
  • Patent number: 9211295
    Abstract: 17?,21-Dihydroxypregna-4,9(11)-diene-3,20-dione and 17?,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters having remarkable antiandrogenic activity are provided, along with methods of using these compounds and processes for their preparation.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: December 15, 2015
    Assignee: CASSIOPEA S.P.A.
    Inventors: Mauro Ajani, Luigi Moro
  • Patent number: 9205057
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: December 8, 2015
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Chidambaram Nachiappan, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Patent number: 9192600
    Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: November 24, 2015
    Assignee: The University of Utah Research Foundation
    Inventor: Tianxin Yang
  • Patent number: 9138457
    Abstract: Provided herein are ophthalmically acceptable pharmaceutical compositions comprising a PRG4 inducing compound in combination with PRG4 (including a lubricant fragments, homologs, or isoforms thereof), and methods of using the same. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: September 22, 2015
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SCHEPENS EYE RESEARCH INSTITUTE
    Inventors: Benjamin Sullivan, Tannin A. Schmidt, David A. Sullivan
  • Patent number: 9132137
    Abstract: A multiphasic estrogenic/progestogenic contraceptive regimen that provides for the reduction or elimination of estrogen in the initial phase is disclosed. Also described is a contraceptive kit that may be used to practice the method of the invention.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: September 15, 2015
    Assignee: Warner Chilcott Company, LLC
    Inventor: Roger M. Boissonneault
  • Patent number: 9107840
    Abstract: The present invention relates to a hormonal contraceptive including at least 120 hormone-containing daily units, which contain 5 to 50 ?g of ethinyloestradiol and 1 to 5 mg of chlormadinone acetate, and optionally 7 to 3 hormone-free daily units for uninterrupted oral administration to women.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: August 18, 2015
    Assignee: Richter Gedeon Nyrt.
    Inventors: Georg Schramm, Rainer Henske
  • Patent number: 9084796
    Abstract: A method of preventing estrogen deficiencies and osteoporosis in menopausal women by continuously orally administering without interruption to menopausal women in need thereof an amount of 0.3 to 3 mg of 17?-estradiol or esters thereof and 0.3 to 1.25 mg of nomegestrol or esters thereof in an amount sufficient to prevent said problems.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: July 21, 2015
    Assignee: LABORATOIRE THERAMEX
    Inventors: Jacques Paris, Jean-Louis Thomas
  • Publication number: 20150148321
    Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 28, 2015
    Inventors: Huw Davies, Debashis Ghosh, Daniel Morton
  • Publication number: 20150141328
    Abstract: Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, IGF-1 or an IGF-1 analogue (e.g. insulin), GH, and mixtures thereof. The pharmaceutical compositions are effective to treat a variety of aliments to the eye including meibomian gland dysfunction, evaporative dry eye disease, lipid abnormalities in meibum or the tear film, and autoimmune diseases such as Sjögren's syndrome.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventors: David A. Sullivan, Juan Ding, Yang Liu, Wendy Kam
  • Patent number: 9034858
    Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: May 19, 2015
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Basawaraj Chickmath, Chidambaram Nachiappan, Mahesh V. Patel, Srinivansan Venkateshwaran
  • Publication number: 20150133417
    Abstract: We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm.
    Type: Application
    Filed: January 21, 2015
    Publication date: May 14, 2015
    Applicant: Diurnal Limited
    Inventors: Hiep Huatan, Richard Ross
  • Patent number: 9029414
    Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.
    Type: Grant
    Filed: September 19, 2009
    Date of Patent: May 12, 2015
    Assignee: Biotechnology Research Corporation
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu
  • Publication number: 20150118285
    Abstract: The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components.
    Type: Application
    Filed: September 10, 2014
    Publication date: April 30, 2015
    Inventors: Gilles H. Tapolsky, David W. Osborne
  • Publication number: 20150110856
    Abstract: The subject invention provides improved testosterone gel formulations.
    Type: Application
    Filed: October 22, 2014
    Publication date: April 23, 2015
    Inventors: Arnaud Grenier, Dario N. Carrara
  • Publication number: 20150111834
    Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.
    Type: Application
    Filed: September 17, 2014
    Publication date: April 23, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
  • Publication number: 20150098909
    Abstract: A soluble fiber lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives dispersed in the soluble-fiber matrix. In some cases, a soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in soluble fiber lozenge provided herein can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Shuzhong Zhuang, Phillip M. Hulan, William J. Burke, Gerd Kobal
  • Publication number: 20150098978
    Abstract: A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an oral cavity.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke, Gerd Kobal
  • Publication number: 20150094290
    Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.
    Type: Application
    Filed: June 16, 2014
    Publication date: April 2, 2015
    Applicant: Acrux DDS Pty Ltd
    Inventors: Timothy Matthias Morgan, Nina Frances Wilkins, Kathryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
  • Publication number: 20150094291
    Abstract: The invention provides a method for improving the emotional development of an infant by performing controlled exposure of the infant aged less than six months old to human fear pheromone, preferably with visual fear stimuli, so that the natural synaptic connections in the brain associated with normal fear mechanisms are stimulated and exercised. This can reduce the occurrence of mental illness later in life, in particular reduce the occurrence of schizophrenia. Advantageously the exposure to fear pheromone and visual fear stimuli is terminated and followed by comforting stimuli such as feeding, physical contact, or comforting or happy visual or audible stimuli such as laughter.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 2, 2015
    Applicant: Opendot Research Co Limited
    Inventor: Derek John GOLDSMITH
  • Patent number: 8993520
    Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: March 31, 2015
    Assignee: Acrux DDS Pty Ltd
    Inventors: Tony Dipietro, Andrew Humberstone, Igor Gonda, Adam Watkinson, Kerrie Setiawan, Nina Wilkins
  • Publication number: 20150087623
    Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
    Type: Application
    Filed: October 8, 2014
    Publication date: March 26, 2015
    Applicant: Acrux DDS Pty Ltd
    Inventors: Tony DIPIETRO, Andrew HUMBERSTONE, Igor GONDA, Adam WATKINSON, Kerrie SETIAWAN, Nina WILKINS
  • Publication number: 20150086635
    Abstract: The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 26, 2015
    Applicant: Alkermes Pharma Ireland Limited
    Inventors: Douglas Hovey, John Pruitt, Tuula Ryde
  • Patent number: 8975245
    Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 10, 2015
    Assignee: Drawbridge Pharmaceuticals Pty Ltd
    Inventors: Juliet Marguerite Goodchild, Colin Stanley Goodchild, Benjamin James Boyd
  • Publication number: 20150064243
    Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs are provided. The pharmaceutical compositions include a therapeutically effective amount of a hydrophobic drug, preferably a steroid; a solubilizer, and a surfactant. The synergistic effect between the hydrophobic drug and the solubilizer results in a pharmaceutical formulation with improved dispersion of both the active agent and the solubilizer. As a result of the improved dispersion, the pharmaceutical composition has improved bioavailability upon administration. Methods of improving the bioavailability of hydrophobic drugs administered to a patient are also provided.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Feng-Jing Chen, Mahesh V. Patel, David T. Fickstad, Huiping Zhang, Chandrashekar Giliyar
  • Patent number: 8969327
    Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: March 3, 2015
    Assignees: Emory University, The Research Foundation of State of New York, Hauptman-Woodward Medical Research Institute
    Inventors: Huw Davies, Dabashis Ghosh, Daniel Morton